Grit Biotechnology clinical trials
The registry lists 30 studies whose lead sponsor is Grit Biotechnology. 17 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 12, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 30studies on the registry
- 17open to participants now
- 7reach primary completion within a year
Get an email when these change. Save the Grit Biotechnology studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
What it is testing
The drugs Grit Biotechnology’s studies test, most open studies first — 5 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
7 of Grit Biotechnology’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- 1JJan ’27’27
- FFeb
- MMar
- 2AApr
- 1MMay
- 1JJun
- JJul
- AAug
- SSep
- OOct
- 2NNov
All 7
- Jan 2027Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancerdimethyl-2-(tetrahydro-2-furanyl)ethylsulfonium · NCT06241781
- Apr 2027Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid TumoursAutologous Tumor-infiltrating Lymphocytes GT307 · NCT06397963
- Apr 2027Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck TumorsAutologous Tumor Infiltrating Lymphocytes GT201 · NCT06190275
- May 2027Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal CancerAutologous Tumor-infiltrating Lymphocytes GT307 · NCT06819280
- Jun 2027Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid TumoursAutologous Tumor-infiltrating Lymphocytes GT307 · NCT06453057
Show 2 moreShow fewer
- Nov 2027A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic AnemiaGT801 · NCT07205315
- Nov 2027A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)NCT07253259
Add all 7 to your calendar (.ics) → With an account.
All 30 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 21
- 22
- 23
- 924
- 25
- 126
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Grit Biotechnology.
- Grit Biotechnology30 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 30 of 30.
- Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical CancerRecruitingNCT06241781Phase 2
- Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid TumorsRecruitingNCT06144671Phase 1/2
- GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell MalignanciesRecruitingNCT06948981Phase 1/2
- GT719 Injection for Moderate to Severe Refractory Autoimmune DiseasesRecruitingNCT07122076Early Phase 1
- GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune DiseasesRecruitingNCT07021209Phase 1
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney DiseasesNot yet recruitingNCT07389499Early Phase 1
- A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid LeukemiaNot yet recruitingNCT07676006Early Phase 1
- A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic AnemiaRecruitingNCT07205315Early Phase 1
- A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune DiseasesRecruitingNCT07333118Early Phase 1
- Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck TumorsRecruitingNCT06190275Not applicable
- GT719 Injection for Moderate to Severe Refractory Autoimmune DiseaseRecruitingNCT07132112Early Phase 1
- Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid TumoursRecruitingNCT06453057Not applicable
- Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal CancerRecruitingNCT06819280Not applicable
- IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell CarcinomaRecruitingNCT06819293Phase 1
- A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)RecruitingNCT07253259Early Phase 1
- Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid TumoursRecruitingNCT06397963Not applicable
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological TumorsRecruitingNCT07131254Early Phase 1
- GT101 Injection for the Treatment of Metastatic or Recurrent Solid TumorsActive, not recruitingNCT05430373Phase 1
- TIL Injection for the Treatment of Metastatic or Recurrent Solid TumorsActive, not recruitingNCT06088472Phase 1
- A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid TumorsWithdrawnNCT07534813Not applicable
- GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid TumorsTerminatedNCT06077903Early Phase 1
- Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid TumorsTerminatedNCT06094426Early Phase 1
- Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)WithdrawnNCT06145802Not applicable
- Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid TumorsTerminatedNCT05430360Phase 1
- Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung CancerTerminatedNCT06519669Not applicable
- Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid TumorsTerminatedNCT05729399Phase 1/2
- Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)TerminatedNCT06191900Not applicable
- GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung CancerTerminatedNCT06235242Not applicable
- Clinical Study of GT201 in the Treatment of Advanced Gynecological TumorsTerminatedNCT06834542Early Phase 1
- Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung AdenocarcinomaTerminatedNCT06491225Phase 1